Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Blouin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|December 30, 2014
Subcutaneous immunoglobulin replacement therapy: ensuring successM Elizabeth M Younger, William Blouin, Carla Duff, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|December 29, 2012
Nursing guidelines for administration of immunoglobulin replacement therapyMary Elizabeth M Younger, Loris Aro, William Blouin, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|December 30, 2014
Subcutaneous immunoglobulin replacement therapy: ensuring successM Elizabeth M Younger, William Blouin, Carla Duff, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|December 29, 2012
Nursing guidelines for administration of immunoglobulin replacement therapyMary Elizabeth M Younger, Loris Aro, William Blouin, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Pageof 1